Keke Wu focuses her practice on advising corporate clients and investment banks on capital markets transactions, such as initial public offerings, investment-grade bond offerings and high-yield bond offerings.
Cooley advised TI Cloud on its $71.7 million initial public offering of 43,530,000 shares at a public offering price of HK$12.85 per share. TI Cloud offers a broad array of cloud-native customer contact solutions that enable enterprises to engage in multichannel customer interactions. Partners Michael Yu and Will Cai led the Cooley team.
Cooley advised GOGOX, an online intracity logistics platform in Asia focused on the transportation of freight and goods in urban areas, on its HK$675 million (US$86 million) initial public offering of 3,120,000 shares (subject to an overallotment option to issue an additional 4,680,000 shares), which now trade on the Hong Kong Stock Exchange. Partners Michael Yu and Will Cai led the Cooley team advising GOGOX, which also included Lisa Yuan, Marcus Chen, Ying Liu, Keke Wu, Jasmine Li, April Wang, Cindy Pan, Shuaiwen Wang, Jieting Zhang and Freeda Li.
Cooley advised Asymchem, a Chinese-based contract development and manufacturing company serving the global pharmaceutical and biotech industry, on its definitive agreement to acquire Snapdragon Chemistry, a US-based chemical technology company. Partner Yiming Liu led the Cooley team.
As a result of the transaction, Asymchem will significantly expand its footprint in the US, offering customers a seamless path from preclinical process R&D through commercial current good manufacturing practice (cGMP) production. Snapdragon will operate as a stand-alone Asymchem division, and continue with its ongoing lab and manufacturing facility expansion for additional capacity to support larger, pilot-scale manufacturing in Waltham, Massachusetts.
"We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits," Hao Hong, chairman and CEO of Asymchem, said in a news release. "Asymchem has been deeply committed to flow chemistry technology development and its application expansion in the pharmaceutical industry for more than a decade. We are excited that this strategic acquisition will further strengthen our capabilities in continuous manufacturing, as well as broadening our service scope and client pool."
Cooley advised Asymchem Laboratories, a contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its HK$7.15 billion (US$916 million) initial public offering – marking the largest healthcare IPO in Hong Kong this year – of 18,415,400 H shares, which now trade on the Hong Kong Stock Exchange. Partners Yiming Liu and Michael Yu led the Cooley team advising Asymchem.